DOJ Backs AbbVie in 340B Drug Pricing Dispute: What’s at Stake? The U.S. Department of Justice (DOJ) is siding with pharmaceutical giant AbbVie in a lawsuit against the state of Colorado, escalating a critical battle over the 340B Drug Pricing Program. This marks the first time the federal government has weighed in on the numerous … Read more
FDA Rejection of Rare Disease Therapy Sparks Debate Over Agency Direction A promising cell therapy developed by Atara Biotherapeutics and Pierre Fabre Pharmaceuticals for a rare blood cancer faced a sudden reversal in its path to FDA approval. Internal reviewers had previously recommended clearance, yet the agency rejected the drug last month, citing insufficient clinical … Read more
GSK’s $950 Million Bet on 35Pharma: A New Wave in Pulmonary Hypertension Treatment? GSK has acquired privately held 35Pharma for $950 million, a move signaling increased industry focus on pulmonary arterial hypertension (PAH). The acquisition centers around HS235, an experimental drug poised to enter clinical trials for PAH, a condition characterized by high blood pressure … Read more
Medicare Drug Price Battles: What Trump’s Plans Mean for Your Wallet The pharmaceutical industry is bracing for potential showdowns with the Trump administration over proposals designed to lower Medicare drug costs. These plans, centered around aligning U.S. Prices with those paid in other developed nations, could dramatically reshape the landscape of prescription drug affordability. But … Read more
Novo Nordisk’s Price Cuts: A Turning Point for GLP-1 Medications? Novo Nordisk’s announcement of significant price reductions for its blockbuster GLP-1 medications – Ozempic, Rybelsus and Wegovy – has sent ripples through the healthcare industry. The move, slated to take effect January 1, 2027, will lower the list price of each drug to $675 per … Read more
The Dawn of Bespoke Medicine: How Individualized Treatments Are Reshaping Healthcare The Food and Drug Administration (FDA) recently released guidance paving the way for the approval of the first truly personalized medicines, designed to address a patient’s unique genetic makeup. This shift, spearheaded by FDA Commissioner Marty Makary and biologics chief Vinay Prasad, marks a … Read more
Bayer Challenges J&J’s Erleada Marketing Claims in Court German pharmaceutical company Bayer has launched a lawsuit against Johnson & Johnson (J&J) and its subsidiary Janssen Biotech, alleging false advertising related to their prostate cancer drugs, Erleada and Nubeqa. The legal action, filed in the United States District Court for the Southern District of New York, … Read more
The Shifting Landscape of Health, Leisure, and Supply Chains: A Look Ahead As another week concludes, the focus shifts to weekend plans and a brief respite from perform. But beyond personal leisure, broader trends are emerging that will shape the coming months and years – from evolving approaches to mental health treatment to disruptions in … Read more
The CMO Shuffle: Why Leadership Changes are Accelerating in Biotech and Pharma The biopharmaceutical industry is experiencing a period of significant leadership transition. Recent moves, like CDR-Life’s appointment of Dimitrios Chondros as Chief Medical Officer (CMO), signal a broader trend of companies recalibrating their strategies and seeking specialized expertise to navigate a rapidly evolving landscape. … Read more
Healthcare Antitrust Battles: A Growing Trend? The Department of Justice (DOJ) and the state of Ohio recently filed a civil antitrust lawsuit against OhioHealth, alleging the health system is using its market power to stifle competition and inflate costs. This action signals a potentially significant shift in how regulators approach the healthcare industry, and it’s … Read more